NCT06579222 Comorbidity Management in Rheumatic Disease.
| NCT ID | NCT06579222 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Western University, Canada |
| Condition | Rheumatoid Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 199 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-06-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 199 participants in total. It began in 2025-05-01 with a primary completion date of 2026-06-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rheumatoid arthritis is a disease where the immune system attacks the body by mistake, causing inflammation of the joints and other body parts. People with rheumatoid arthritis are at higher risk of infections, heart problems, and bone issues compared to others. They regularly see rheumatologists, arthritis care physicians, to manage their disease. However, managing these other health problems alongside their main treatment is difficult for rheumatologists due to limited resources. This clinical study is being conducted to see if adding a family doctor to a team of rheumatologists can help. Rheumatologists will complete a case report form about the patient's health and send them to a special family physician clinic. This clinic will focus on improving vaccination against diseases, heart health, and bone strength. They will check if patients need special vaccines to protect them from infections. They will screen for heart disease using blood pressure measurements, and order blood work for high cholesterol and diabetes if needed. They will also review bone health and send people for tests to check their bone density if needed. A change in routines and medications may be recommended after their checkup. Rheumatologists will complete another case report about the patient's health 6 months after their family doctor appointment. The study will assess how these markers of health management improve after this family doctor joins the team. It hopes to prove that this new way of working in the community will give people with rheumatoid arthritis better protection against certain infections, heart problems and weak bones.
Eligibility Criteria
Inclusion Criteria: * Patients of the Waterloo Rheumatology Community Clinic * Aged 18 to 80 years of age * Diagnosis of rheumatoid arthritis * Minimum of limited working proficiency in English * No significant cognitive impairment that can inhibit their ability to engage in the study Exclusion Criteria: * Age less than 18 years or greater than 80 years * Significant cognitive impairment that impedes ability to engage in the study * Unwilling to participate in the study * Patients currently pregnant will be excluded from the study
Contact & Investigator
Cassandra Schulz
PRINCIPAL INVESTIGATOR
Western University
Frequently Asked Questions
Who can join the NCT06579222 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06579222 currently recruiting?
Yes, NCT06579222 is actively recruiting participants. Contact the research team at wrheumatologystudy@gmail.com for enrollment information.
Where is the NCT06579222 trial being conducted?
This trial is being conducted at Waterloo, Canada.
Who is sponsoring the NCT06579222 clinical trial?
NCT06579222 is sponsored by Western University, Canada. The principal investigator is Cassandra Schulz at Western University. The trial plans to enroll 199 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.